SCHEMBL2774875

SCHEMBL2774875

CCc1cnc(OC2CCN(C(=O)OC(C)(C)C)CC2)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 10/20 0.51
PDE4A P27815 2/20 0.47
PDE4B Q07343 2/20 0.47
PDE4C Q08493 2/20 0.47
PDE4D Q08499 2/20 0.47
PIK3CD O00329 1/20 0.46
CACNB4 O00305 1/20 0.46
CACNA1A O00555 1/20 0.46
CACNA1G O43497 1/20 0.46
CACNG3 O60359 1/20 0.46
CACNA1F O60840 1/20 0.46
CACNA1H O95180 1/20 0.46
CACNB3 P54284 1/20 0.46
CACNA2D1 P54289 1/20 0.46
CACNG7 P62955 1/20 0.46
CACNA1B Q00975 1/20 0.46
CACNA1D Q01668 1/20 0.46
CACNB1 Q02641 1/20 0.46
CACNG1 Q06432 1/20 0.46
CACNB2 Q08289 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20303489 0.87 GPR119 (0.48) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL2538047 0.85 GPR119 (0.53) GPR119PIK3CDNPBWR1MCHR1HPGD
SCHEMBL2774428 0.85 GPR119 (0.53) GPR119PIK3CDNPBWR1MCHR1HPGD
SCHEMBL4469107 0.85 GPR119 (0.53) GPR119NPBWR1MCHR1HPGD
SCHEMBL20138026 0.85 GPR119 (0.63) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL3343105 0.84 GPR119 (0.52) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL20303652 0.84 GPR119 (0.52) GPR119PDE4APDE4BPDE4CPDE4D
SCHEMBL4714125 0.83 GPR119 (0.62) GPR119
SCHEMBL2774561 0.83 GPR119 (0.51) GPR119NPBWR1MCHR1
SCHEMBL29716446 0.83 GPR119 (0.53) GPR119NPBWR1MCHR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053933-A1 HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-03 US disclosed
EP-2258697-A1 HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2010-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053933-A1 HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE F12, F2, C3AR1 GPR119 1336/4885PDE4A 2510/4885PDE4B 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.